Skip to Main Content

A gene therapy for Huntington’s disease made by the Dutch biotech firm Uniqure showed early promise in a preliminary study of a handful of patients, the company said Wednesday.

Evaluable data were available from only four patients who had received the treatment, code-named AMT-130, and three in a control group who had undergone a sham treatment. All were in the early stages of the fatal neurodegenerative disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment